Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, September 1, 2014. To access the conference call, follow these instructions:
Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
Passcode: 73168608 (Nektar Therapeutics is the host)In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platform. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Movantik™ (naloxegol), an investigational drug candidate, which has been filed for regulatory approvals in the U.S., Europe and Canada as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes Movantik fixed dose combination products (formerly NKTR-119), an earlier stage development program that is a co-formulation of Movantik and an opioid. NKTR-181, a novel mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatm
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Infectious Disease Diagnostics Market by Product, Application, Technology, ... to their offering. , The infectious disease ... 7.9% to reach $18,156.2 million by 2019 from $12,422.8 ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... Calif., Aug. 20 Jazz Pharmaceuticals, Inc. (Nasdaq: ... Committee of the U.S. Food and Drug Administration (FDA), ... and Risk Management Advisory Committee, voted 20-2 that the ... for the treatment of fibromyalgia with the currently proposed ...
... Cumberland Pharmaceuticals Inc.(Nasdaq: CPIX ) today ... its review of the supplemental new drug application (sNDA) for ... with non-acetaminophen acute liver failure. The review has been extended ... Fee Act (PDUFA) goal date in December 2010. ...
Cached Medicine Technology:Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia 2Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application 2Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application 3
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... so will potential risks, researcher warns , FRIDAY, May ... defibrillators and cochlear implants, are becoming vulnerable to "infection" ... To prove his point, Mark Gasson, a scientist at ... himself to become "Exhibit A." , Gasson said he ...
... (May 28, 2010)Cancer of the pancreasa glandular organ ... and hormonesseldom is detected in early stages, making treatment ... research from Fox Chase Cancer Center finds that patients ... chemotherapy and radiation survive four times as long, on ...
... ... ... Clubs International Foundation (LCIF), will appear in Monday’s National Memorial Day Parade along ... who are Lions Clubs members. , , ,One of the WWII veterans on the float will ...
... ... solutions arena with the addition of two respected Atlanta-area surgical assistant practices: Omni Surgical ... ... (JSA) has expanded its national presence in the practice management solutions arena with the ...
... Khanna ... ... have had a symbiotic relationship to advance vision in people suffering from presbyopia or cataracts. ... RK or macular degeneration. The Crystalens is the only FDA approved accommodating intraocular lens ...
... are studying the role that statins lifesavers for tens ... play in causing disabling tendon ruptures. Francesca Dwamena, ... of Medicine, is leading the study, which will analyze more ... by a grant from the Blue Cross Blue Shield of ...
Cached Medicine News:Health News: Scientist Becomes First Human 'Infected' With Computer Virus 2Health News:Response to preoperative therapy may predict survival in pancreatic cancer patients 2Health News:Chairman Al Brandel of Lions Clubs International Foundation to Appear in Washington DC's National Memorial Day Parade 2Health News:Jackson Surgical Assistants Expands Its National Presence by Merging with Two Atlanta Area Practices 2Health News:Jackson Surgical Assistants Expands Its National Presence by Merging with Two Atlanta Area Practices 3Health News:Khannna Institute to offer Crystalens in Quarter Diopter Steps 2Health News:MSU team studies connection between statins, tendon ruptures 2
Six inch wide elastic belt transfers the apron weight off the shoulders. 0.5mm front and 0.25mm back with a generous overlap for double protection. Shoulder pads included. Also available without wide...
6" wide elastic belt transfers the apron weight off the shoulders to the hips making this apron the most comfortable for long procedures. Adjustable. Velcro keeps apron snug....
... single-use, direct current stimulator ... 0.5, 1.0, and 2.0mA ... needle as the grounding ... flow" confirmation light is ...
The NS242 is a base level constant current Conventional Peripheral Nerve Stimulator only. It uses conventional stimulation patterns only to monitor neuromuscular blocks i.e. Single Twitch, Train of F...
Medicine Products: